October 11, 2017 10:26 AM EDT
News Briefing

Ul­tragenyx wins pri­or­i­ty re­view for buro­sum­ab; Gen­fit rais­ing €150M for PhI­II NASH study

Shehla Shakoor

Managing Director

→ Ul­tragenyx $RARE and its part­ners at Ky­owa Hakko Kirin land­ed a pri­or­i­ty re­view for buro­sum­ab to treat pe­di­atric and adult pa­tients with X …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times